TauRx Therapeutics

Privately held: no public share price · New Zealand / United Kingdom

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
Tau aggregation; AcetylcholineSmall molecule
Alzheimer's Disease

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

29 July 2024Filing acceptedHydromethylthionine mesylateMHRA accepted the UK marketing authorisation application for HMTM
UK, MHRA · Source ↗

Financial reports

No financial reports recorded.